Myovant Sciences Ltd. (MYOV) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
SUITE 1, 3RD FLOOR LONDON, SW1Y 4LB |
| State of Incorp. | CA |
| Fiscal Year End | March 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments, including: | 684,900 | 79,641 | 156,074 | 108,624 | 180,838 | |||
| Cash and cash equivalents | 674,493 | 76,644 | 156,074 | 108,624 | 180,838 | |||
| Short-term investments | 10,435 | 2,997 | ||||||
| Other undisclosed cash, cash equivalents, and short-term investments | (28) | |||||||
| Restricted cash and investments | 1,125 | |||||||
| Receivables | 3,570 | 524 | 1,000 | 105 | ||||
| Inventory, net of allowances, customer advances and progress billings | 2,611 | |||||||
| Inventory | 2,611 | |||||||
| Other undisclosed current assets | 13,564 | 8,269 | 9,069 | 5,139 | 3,221 | |||
| Total current assets: | 704,645 | 87,910 | 166,792 | 114,763 | 184,164 | |||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 9,655 | 11,146 | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 3,300 | 2,497 | 2,071 | 1,273 | 906 | |||
| Other noncurrent assets | 7,427 | 4,373 | 4,114 | 3,065 | ||||
| Other undisclosed noncurrent assets | 208 | |||||||
| Total noncurrent assets: | 20,382 | 18,016 | 6,185 | 4,338 | 1,114 | |||
| TOTAL ASSETS: | 725,027 | 105,926 | 172,977 | 119,101 | 185,278 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 44,630 | 44,394 | 11,019 | 35,125 | 15,307 | |||
| Interest and dividends payable | 1,077 | 282 | ||||||
| Employee-related liabilities | 20,571 | |||||||
| Accounts payable | 17,809 | 15,334 | 4,578 | 3,329 | ||||
| Accrued liabilities | 6,250 | 29,060 | 53,614 | 30,265 | 11,978 | |||
| Other undisclosed accounts payable and accrued liabilities | (43,672) | |||||||
| Deferred revenue | 40,000 | ✕ | ✕ | ✕ | ||||
| Debt | 1,516 | 6,142 | ||||||
| Deferred compensation liability | 21,636 | |||||||
| Due to related parties | 543 | 121 | 1,960 | 3,030 | ||||
| Other undisclosed current liabilities | 214,531 | 15 | 54,691 | |||||
| Total current liabilities: | 281,340 | 85,925 | 71,973 | 37,085 | 18,337 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 9,189 | 10,996 | 93,240 | |||||
| Long-term debt, excluding current maturities | 93,240 | |||||||
| Liabilities, other than long-term debt | 759,016 | 117,282 | 1,157 | 408 | 165 | |||
| Deferred revenue and credits | ✕ | ✕ | ✕ | ✕ | 408 | 113 | ||
| Deferred revenue | 397,369 | ✕ | ✕ | ✕ | ||||
| Deferred rent credit | 1,157 | ✕ | ✕ | |||||
| Due to related parties | 358,700 | 113,700 | ||||||
| Other liabilities | 2,947 | 3,582 | ||||||
| Operating lease, liability | 9,189 | 10,996 | ✕ | ✕ | ✕ | |||
| Derivative instruments and hedges, liabilities | 52 | |||||||
| Other undisclosed noncurrent liabilities | 29,447 | 2,273 | 43,879 | |||||
| Total noncurrent liabilities: | 797,652 | 128,278 | 96,670 | 44,287 | 165 | |||
| Total liabilities: | 1,078,992 | 214,203 | 168,643 | 81,372 | 18,502 | |||
| Equity | ||||||||
| Equity, attributable to parent | (353,965) | (108,277) | 4,334 | 37,729 | 166,776 | |||
| Common stock | 2 | 2 | 1 | 1 | 1 | |||
| Common stock, share subscribed but unissued, subscriptions receivable | (1) | |||||||
| Additional paid in capital | 709,466 | 684,381 | 505,851 | 266,178 | 251,733 | |||
| Accumulated other comprehensive income (loss) | (17,285) | (1,646) | 507 | 24 | 140 | |||
| Accumulated deficit | (1,046,148) | (791,014) | (502,025) | (228,474) | (85,097) | |||
| Total equity: | (353,965) | (108,277) | 4,334 | 37,729 | 166,776 | |||
| TOTAL LIABILITIES AND EQUITY: | 725,027 | 105,926 | 172,977 | 119,101 | 185,278 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 59,317 | ||||||
| Gross profit: | 59,317 | ||||||
| Operating expenses | (318,136) | (274,887) | (264,826) | (141,063) | (55,857) | ||
| Other undisclosed operating loss | (1,965) | (8,249) | (1,979) | (27,657) | |||
| Operating loss: | (260,784) | (274,887) | (273,075) | (143,042) | (83,514) | ||
| Nonoperating income (expense) | 16,387 | 4,173 | (116) | 140 | |||
| Investment income, nonoperating | 211 | 2,552 | |||||
| Gain (loss), foreign currency transaction, before tax | 16,176 | (116) | 140 | ||||
| Other nonoperating income | 1,621 | ||||||
| Interest and debt expense | (10,401) | (17,514) | (8,821) | (2,046) | |||
| Loss from continuing operations before equity method investments, income taxes: | (254,798) | (288,228) | (281,896) | (145,204) | (83,374) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | 8,821 | 2,162 | (140) | ||||
| Loss from continuing operations before income taxes: | (254,798) | (288,228) | (273,075) | (143,042) | (83,514) | ||
| Income tax expense (benefit) | (336) | (761) | (476) | (213) | 74 | ||
| Loss from continuing operations: | (255,134) | (288,989) | (273,551) | (143,255) | (83,440) | ||
| Loss before gain (loss) on sale of properties: | (255,134) | (288,989) | (273,551) | (143,255) | (83,440) | ||
| Net loss available to common stockholders, diluted: | (255,134) | (288,989) | (273,551) | (143,255) | (83,440) | ||
Comprehensive Income ($ in thousands)
| 3/31/2022 | 3/31/2021 | 3/31/2020 | 3/31/2019 | 3/31/2018 | 3/31/2017 | ||
|---|---|---|---|---|---|---|---|
| Net loss: | (255,134) | (288,989) | (273,551) | (143,255) | (83,440) | ||
| Comprehensive loss: | (255,134) | (288,989) | (273,551) | (143,255) | (83,440) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (15,639) | (2,153) | 483 | (116) | 140 | ||
| Comprehensive loss, net of tax, attributable to parent: | (270,773) | (291,142) | (273,068) | (143,371) | (83,300) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.